NASDAQ:KNTE

Kinnate Biopharma (KNTE) Stock Forecast, Price & News

$4.24

-0.06 (-1.40%)

(As of 06/2/2023 ET)

Compare

Today's Range: $4.14
▼
$4.40
50-Day Range: $2.33
▼
$6.84
52-Week Range: $2.32
▼
$15.86

Volume: 338,864 shs
Average Volume: 303,679 shs
Market Capitalization: $197.46 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $17.25

Kinnate Biopharma MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.75 Rating Score
Upside/Downside: 306.8% Upside
$17.25 Price Target
Short Interest: Bearish
8.75% of Float Sold Short
Dividend Strength: N/A
Sustainability: -0.81
Upright™ Environmental Score
News Sentiment: N/A
Insider Trading: Acquiring Shares
$9.07 M Bought Last Quarter
Proj. Earnings Growth: Growing
From ($3.03) to ($2.75) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.69 out of 5 stars

Medical Sector

75th out of 983 stocks

Pharmaceutical Preparations Industry

29th out of 486 stocks

4.4

Analyst's Opinion

Consensus Rating
Kinnate Biopharma has received a consensus rating of Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $17.25, Kinnate Biopharma has a forecasted upside of 306.8% from its current price of $4.24.
Amount of Analyst Coverage
Kinnate Biopharma has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

1.0

Short Interest

Percentage of Shares Shorted
8.75% of the float of Kinnate Biopharma has been sold short.
Short Interest Ratio / Days to Cover
Kinnate Biopharma has a short interest ratio ("days to cover") of 4.3.
Change versus previous month
Short interest in Kinnate Biopharma has recently increased by 10.60%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Kinnate Biopharma does not currently pay a dividend.
Dividend Growth
Kinnate Biopharma does not have a long track record of dividend growth.

4.7

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Kinnate Biopharma has received a 74.24% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Preclinical research services for physical health" and "Clinical research services for cancer" products. See details.
Environmental Sustainability
The Environmental Impact score for Kinnate Biopharma is -0.81.

0.6

News and Social Media Coverage

News Coverage This Week
MarketBeat has tracked 1 news article for Kinnate Biopharma this week, compared to 2 articles on an average week.
Search Interest
47 people have searched for KNTE on MarketBeat in the last 30 days. This is an increase of 1,467% compared to the previous 30 days.
MarketBeat Follows
Only 1 people have added Kinnate Biopharma to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days.

5.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Kinnate Biopharma insiders have bought more of their company's stock than they have sold. Specifically, they have bought $9,074,491.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
37.90% of the stock of Kinnate Biopharma is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
98.68% of the stock of Kinnate Biopharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.3

Earnings and Valuation

Earnings Growth
Earnings for Kinnate Biopharma are expected to grow in the coming year, from ($3.03) to ($2.75) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Kinnate Biopharma is -1.53, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Kinnate Biopharma is -1.53, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Kinnate Biopharma has a P/B Ratio of 0.89. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Kinnate Biopharma (NASDAQ:KNTE) Stock

Kinnate Biopharma Inc., a biopharmaceutical company, focuses on the discovery and development of small molecule kinase inhibitors to treat genomically defined cancers in the United States. The company develops KIN-2787, a rapidly accelerated fibrosarcoma inhibitor for the treatment of patients with lung cancer, melanoma, and other solid tumors; KIN-3248 small-molecule kinase inhibitors that target cancer-associated alterations in fibroblast growth factor receptors FGFR2 and FGFR3 genes; and small molecule research programs, including Cyclin-Dependent Kinase 12(CDK12) inhibitor in its KIN004 program. The company was incorporated in 2018 and is headquartered in San Francisco, California. Kinnate Biopharma Inc. is a former subsidiary of Fount Therapeutics, LLC.

Receive KNTE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Kinnate Biopharma and its competitors with MarketBeat's FREE daily newsletter.

KNTE Stock News Headlines

May 30, 2023 | markets.businessinsider.com

Stifel Nicolaus Reaffirms Their Hold Rating on Kinnate Biopharma (KNTE)

May 24, 2023 | americanbankingnews.com

Kinnate Biopharma Inc. (NASDAQ:KNTE) to Post Q2 2023 Earnings of ($0.78) Per Share, HC Wainwright Forecasts

June 3, 2023 | Vantage Point (Ad)

We Called (ARWR) In Advance, Which Stocks Are Next?

Nearly 56% gains in 30 days! This bullish trend reversal was not only forecasted by A.I., but we called it 1 – 3 days in advance. If you have any money invested in the markets…even just your retirement, you’ll want to see this. Plus, it’s FREE - the training is only an hour & LIVE.

May 22, 2023 | americanbankingnews.com

Kinnate Biopharma (NASDAQ:KNTE) Earns Maintains Rating from 500.com

May 21, 2023 | americanbankingnews.com

HC Wainwright Cuts Kinnate Biopharma (NASDAQ:KNTE) Price Target to $24.00

May 18, 2023 | markets.businessinsider.com

Kinnate Biopharma in Focus: Analyst's Adjusted Price Target and the Potential of KIN-3248

May 18, 2023 | markets.businessinsider.com

Expert Ratings for Kinnate Biopharma

May 18, 2023 | markets.businessinsider.com

H.C. Wainwright Sticks to Its Buy Rating for Kinnate Biopharma (KNTE)

June 3, 2023 | Vantage Point (Ad)

We Called (ARWR) In Advance, Which Stocks Are Next?

May 14, 2023 | americanbankingnews.com

Kinnate Biopharma (NASDAQ:KNTE) Releases Earnings Results, Meets Expectations

May 12, 2023 | msn.com

Stifel Maintains Kinnate Biopharma (KNTE) Hold Recommendation

May 12, 2023 | msn.com

Wedbush Reiterates Kinnate Biopharma (KNTE) Outperform Recommendation

May 12, 2023 | marketwatch.com

8-K: Kinnate Biopharma Inc.

May 12, 2023 | markets.businessinsider.com

Wedbush Sticks to Their Buy Rating for Kinnate Biopharma (KNTE)

May 12, 2023 | markets.businessinsider.com

Goldman Sachs Keeps Their Buy Rating on Kinnate Biopharma (KNTE)

May 11, 2023 | finance.yahoo.com

Kinnate Biopharma Inc. Reports First Quarter 2023 Financial Results and Recent Corporate Updates

May 11, 2023 | americanbankingnews.com

Kinnate Biopharma Inc. (NASDAQ:KNTE) Director James B. Tananbaum Acquires 1,780,000 Shares

May 10, 2023 | finance.yahoo.com

Why Earnings Season Could Be Great for Kinnate Biopharma (KNTE)

May 10, 2023 | americanbankingnews.com

Orbimed Advisors Llc Acquires 479,909 Shares of Kinnate Biopharma Inc. (NASDAQ:KNTE) Stock

May 7, 2023 | americanbankingnews.com

Mustang Bio (NASDAQ:MBIO) versus Kinnate Biopharma (NASDAQ:KNTE) Critical Contrast

May 5, 2023 | americanbankingnews.com

Kinnate Biopharma Inc. (NASDAQ:KNTE) Director Acquires $894,409.95 in Stock

May 5, 2023 | americanbankingnews.com

Kinnate Biopharma Inc. (NASDAQ:KNTE) Director Carl L. Gordon Purchases 716,157 Shares

May 4, 2023 | msn.com

Orbimed Boosts Kinnate Biopharma Stake With 1.4 Million Share Purchase

April 22, 2023 | americanbankingnews.com

Kinnate Biopharma (NASDAQ:KNTE) Price Target Lowered to $25.00 at HC Wainwright

April 22, 2023 | americanbankingnews.com

Kinnate Biopharma (NASDAQ:KNTE) Price Target Cut to $26.00

April 22, 2023 | americanbankingnews.com

Q2 2023 EPS Estimates for Kinnate Biopharma Inc. Decreased by Analyst (NASDAQ:KNTE)

April 22, 2023 | americanbankingnews.com

Q1 2023 Earnings Forecast for Kinnate Biopharma Inc. (NASDAQ:KNTE) Issued By Wedbush

See More Headlines

KNTE Price History

30 days | 90 days | 365 days | Advanced Chart

KNTE Company Calendar

Last Earnings: 5/11/2023
Today: 6/02/2023
Next Earnings (Estimated): 8/10/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:KNTE
CUSIP: N/A
CIK: 1797768
Web: www.kinnate.com
Phone: 858-299-4699
Fax: N/A
Employees: 61
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $17.25
High Stock Price Forecast: $26.00
Low Stock Price Forecast: $5.00
Forecasted Upside/Downside: +296.6%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.75
Research Coverage: 4 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($2.77)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-116,270,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -50.53%
Return on Assets: -42.59%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 11.31
Quick Ratio: 11.31

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $4.78 per share
Price / Book: 0.91

Miscellaneous

Outstanding Shares: 46,570,000
Free Float: 28,922,000
Market Cap: $202.58 million
Optionable: Not Optionable
Beta: 0.18

Key Executives

Mr. Nima Farzan M.B.A. (Age 47)
Pres, CEO & Director
Comp: $778.92k

Ms. Neha Krishnamohan (Age 36)
CFO, Principal Accounting Officer and Exec. VP of Corp. Devel.
Comp: $459.52k

Mr. Mark A. Meltz (Age 49)
COO, Gen. Counsel, Treasurer & Sec.
Comp: $586.49k

Ms. Priyanka Shah
VP of Investor Relations & Communications

Ms. Barbara Warren
VP of People & Culture

Dr. Richard Thomas Williams MBBS (Age 54)
Ph.D., Chief Medical Officer

Dr. Robert Kania Ph.D.
Sr. VP of Drug Discovery

Mr. Jason Hampson M.D.
VP and Head of Regulatory Affairs & Quality

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

KNTE Stock - Frequently Asked Questions

Should I buy or sell Kinnate Biopharma stock right now?: 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kinnate Biopharma in the last twelve months. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" KNTE shares.
View KNTE analyst ratings or view top-rated stocks.
What is Kinnate Biopharma's stock price forecast for 2023?: 4 Wall Street analysts have issued 1-year target prices for Kinnate Biopharma's shares. Their KNTE share price forecasts range from $5.00 to $26.00. On average, they anticipate the company's share price to reach $17.25 in the next twelve months. This suggests a possible upside of 296.6% from the stock's current price.
View analysts price targets for KNTE or view top-rated stocks among Wall Street analysts.
How have KNTE shares performed in 2023?: Kinnate Biopharma's stock was trading at $6.10 at the beginning of the year. Since then, KNTE stock has decreased by 28.7% and is now trading at $4.35.
View the best growth stocks for 2023 here.
When is Kinnate Biopharma's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, August 10th 2023.
View our KNTE earnings forecast.
How were Kinnate Biopharma's earnings last quarter?: Kinnate Biopharma Inc. (NASDAQ:KNTE) posted its earnings results on Thursday, May, 11th. The company reported ($0.73) EPS for the quarter, meeting analysts' consensus estimates of ($0.73).
What ETF holds Kinnate Biopharma's stock ?: BlackRock Future Health ETF holds 553 shares of KNTE stock, representing 0.02% of its portfolio.

When did Kinnate Biopharma IPO?: (KNTE) raised $170 million in an initial public offering on Thursday, December 3rd 2020. The company issued 10,000,000 shares at $16.00-$18.00 per share. Goldman Sachs, SVB Leerink, Piper Sandler and Wedbush PacGrow served as the underwriters for the IPO.
What is Kinnate Biopharma's stock symbol?: Kinnate Biopharma trades on the NASDAQ under the ticker symbol "KNTE."
Who are Kinnate Biopharma's major shareholders?: Kinnate Biopharma's stock is owned by many different retail and institutional investors. Top institutional shareholders include BlackRock Inc. (4.89%), Foresite Capital Management V LLC (4.24%), FMR LLC (3.54%), State Street Corp (1.00%), Geode Capital Management LLC (0.96%) and Charles Schwab Investment Management Inc. (0.30%). Insiders that own company stock include Carl L Gordon, James B Tananbaum, Orbimed Advisors Llc and Richard Thomas Williams.
View institutional ownership trends.
How do I buy shares of Kinnate Biopharma?: Shares of KNTE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Kinnate Biopharma's stock price today?: One share of KNTE stock can currently be purchased for approximately $4.35.
How much money does Kinnate Biopharma make?: Kinnate Biopharma (NASDAQ:KNTE) has a market capitalization of $202.58 million. The company earns $-116,270,000.00 in net income (profit) each year or ($2.77) on an earnings per share basis.
How can I contact Kinnate Biopharma?: The official website for the company is www.kinnate.com. The company can be reached via phone at 858-299-4699 or via email at investors@kinnate.com.

This page (NASDAQ:KNTE) was last updated on 6/3/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Kinnate Biopharma (KNTE) Stock Forecast, Price & News

Kinnate Biopharma MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Kinnate Biopharma (NASDAQ:KNTE) Stock

KNTE Stock News Headlines

KNTE Price History

KNTE Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

KNTE Stock - Frequently Asked Questions

Overall MarketRank^™